Cargando…
Circadian transcriptome analysis in human fibroblasts from Hunter syndrome and impact of iduronate-2-sulfatase treatment
BACKGROUND: Hunter syndrome (HS) is a lysosomal storage disease caused by iduronate-2-sulfatase (IDS) deficiency and loss of ability to break down and recycle the glycosaminoglycans, heparan and dermatan sulfate, leading to impairment of cellular processes and cell death. Cell activities and functio...
Autores principales: | Mazzoccoli, Gianluigi, Tomanin, Rosella, Mazza, Tommaso, D’Avanzo, Francesca, Salvalaio, Marika, Rigon, Laura, Zanetti, Alessandra, Pazienza, Valerio, Francavilla, Massimo, Giuliani, Francesco, Vinciguerra, Manlio, Scarpa, Maurizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851237/ https://www.ncbi.nlm.nih.gov/pubmed/24083598 http://dx.doi.org/10.1186/1755-8794-6-37 |
Ejemplares similares
-
A novel CRISPR/Cas9-based iduronate-2-sulfatase (IDS) knockout human neuronal cell line reveals earliest pathological changes
por: Badenetti, Lorenzo, et al.
Publicado: (2023) -
Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model
por: Salvalaio, Marika, et al.
Publicado: (2017) -
Insights into Hunter syndrome from the structure of iduronate-2-sulfatase
por: Demydchuk, Mykhaylo, et al.
Publicado: (2017) -
Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment
por: D’Avanzo, Francesca, et al.
Publicado: (2020) -
Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy
por: Maccari, Francesca, et al.
Publicado: (2022)